# Cancer Epidemiology, Biomarkers \& Prevention 

## Coronary Artery Disease in REDUCE - Letter

Steven Lehrer and Sheryl Green
Cancer Epidemiol Biomarkers Prev 2012;21:1226. Published OnlineFirst May 9, 2012.

| Updated Version | Access the most recent version of this article at: <br> doi:10.1158/1055-9965.EPI-12-0397 |
| :--- | :--- |

Cited Articles This article cites 3 articles, 2 of which you can access for free at: http://cebp.aacrjournals.org/content/21/7/1226.full.htm|\#ref-list-1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.
Reprints and Subscriptions

Permissions

To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.

Letter to the Editor

# Coronary Artery Disease in REDUCE - Letter 

Steven Lehrer and Sheryl Green

In a post hoc hypothesis-developing secondary analysis, Thomas and colleagues found that coronary artery disease was associated with a $35 \%$ increased risk of prostate cancer diagnosis (1). Thomas and colleagues suggest that if this association is confirmed in future studies, further analysis of this relationship and the potential biologic mechanisms by which coronary artery disease mediates this augmentation in prostate cancer risk are warranted. We have analyzed the correlation of prostate cancer death rates in 50 U.S. states and the District of Columbia with deaths from heart disease. Our analysis confirms the finding of Thomas and colleagues.

Data on prostate cancer mortality are from Table 2.23.1.2M, Prostate. Age-Adjusted Cancer Death Rates and $95 \%$ Confidence Intervals by U.S. Census Region and Division, State, and Race and Ethnicity, United States, United States Cancer Statistics (USCS) 2007, Cancer Types Grouped by State and Region (http:// apps.nccd.cdc.gov/uscs/cancersbystateandregion.aspx).

Authors' Affiliation: Department of Radiation Oncology, Mount Sinai School of Medicine, New York

Corresponding Author: Steven Lehrer, Mount Sinai Medical Center, Box 1236, New York, NY 10029. Phone: 212-765-7132; Fax: 212-245-9708; E-mail: stevenlehrer@hotmail.com
doi: 10.1158/1055-9965.EPI-12-0397
©(2012 American Association for Cancer Research.

## References

1. Thomas JA, Gerber L, Banez LL, Moreira DM, Rittmaster RS, Andriole GL, et al. Prostate cancer risk in men with baseline history of coronary artery disease: results from the REDUCE study. Cancer Epidemiol Biomarkers Prev 2012;21:576-81.

Data on age adjusted deaths from heart disease are from Table 29: Deaths: Final Data for 2006. National Vital Statistics Reports (2). Data on race distribution by state are from the U.S. Census, 2010 (http:/ /2010.census.gov/ 2010census/data/).
There was a significant correlation between prostate cancer mortality and heart disease mortality ( $r=0.314$, $P=0.027$ ). Because the incidence of prostate cancer is lower in whites than in blacks (3), multivariate linear regression was conducted with prostate cancer mortality as the dependent variable, heart disease mortality, and percentage of white population by state as independent variables. The correlation between prostate cancer mortality and heart disease mortality was significant ( $P=0.038$ ), controlling for the effect of race ( $P=0.811$ ).
Hypothetically, there are common causes of coronary artery disease and prostate cancer, and the 50 U.S. States and District of Columbia differ in the extent of the common causes. If these common causes can be substantiated measures known to reduce coronary artery disease might also reduce prostate cancer risk.

## Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed by the authors.

Received April 6, 2012; accepted April 16, 2012; published OnlineFirst May 31, 2012.
2. Heron M, Hoyert DL, Murphy SL, Xu J, Kochanek KD, Tejada-Vera B Deaths: final data for 2006. Natl Vital Stat Rep 2009;57:1-134.
3. Pienta KJ, Esper PS. Risk factors for prostate cancer. Ann Intern Med 1993;118:793-803

